Explore Business Standard
Explore Business Standard
The revenue stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Operating Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
PBDT stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Profit Before Tax stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This corresponds to a year-on-year *(YoY) decline of per cent.
Net Profit stands at ₹ crore, reflecting a quarter-on-quarter *(QoQ) decrease of per cent from ₹ crore. This represents a per cent year-on-year *(YoY) decline for the same year.
| Category | Q3 FY25-26 | Q3 FY24-25 | Change % | FY24-25 | FY23-24 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 4,173.00 | 3,821.40 | 9.20 | 15,261.70 | 14,755.70 | 3.43 |
| Expenses | 3,632.90 | 3,069.60 | 18.35 | 12,095.40 | 11,552.80 | 4.70 |
| Other Income | 117.30 | 52.90 | 121.74 | 1,304.70 | 865.50 | 50.75 |
| Operating Profit | 540.10 | 751.80 | -28.16 | 4,471.00 | 4,068.40 | 9.90 |
| Depreciation | 515.30 | 425.40 | 21.13 | 1,687.00 | 1,568.80 | 7.53 |
| Interest | 209.90 | 223.40 | -6.04 | 897.40 | 974.40 | -7.90 |
| Profit Before Tax | -67.80 | 155.90 | -143.49 | 1,886.60 | 1,525.20 | 23.70 |
| Tax | -16.00 | 74.80 | -121.39 | 389.20 | 314.30 | 23.83 |
| Net Profit | -51.80 | 81.10 | -163.87 | 1,429.40 | 1,297.80 | 10.14 |
| Category | Q3 FY25-26 | Q3 FY24-25 | Change % | FY24-25 | FY23-24 | Change % |
|---|---|---|---|---|---|---|
| Total Revenue | 621.30 | 562.80 | 10.39 | 2,242.60 | 2,127.30 | 5.42 |
| Expenses | 744.30 | 531.50 | 40.04 | 2,066.80 | 1,864.60 | 10.84 |
| Other Income | 74.80 | 671.70 | -88.86 | 849.80 | 207.50 | 309.54 |
| Operating Profit | 345.60 | 1,098.80 | -68.55 | 1,025.60 | 470.20 | 118.12 |
| Depreciation | 34.00 | 33.80 | 0.59 | 127.80 | 121.10 | 5.53 |
| Interest | 2.30 | 65.30 | -96.48 | 236.90 | 198.80 | 19.16 |
| Profit Before Tax | -84.50 | 603.90 | -113.99 | 660.90 | 150.30 | 339.72 |
| Tax | -8.10 | 19.90 | -140.70 | 50.50 | 15.10 | 234.44 |
| Net Profit | -76.40 | 584.00 | -113.08 | 609.30 | 119.30 | 410.73 |
| Category | Q3 FY25-26 | Q2 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 4,173.00 | 4,295.50 | -2.85 |
| Expenses | 3,632.90 | 3,472.00 | 4.63 |
| Other Income | 117.30 | 93.00 | 26.13 |
| Operating Profit | 540.10 | 823.50 | -34.41 |
| Depreciation | 515.30 | 473.00 | 8.94 |
| Interest | 209.90 | 272.20 | -22.89 |
| Profit Before Tax | -67.80 | 171.30 | -139.58 |
| Tax | -16.00 | 38.50 | -141.56 |
| Net Profit | -51.80 | 132.80 | -139.01 |
| Category | Q3 FY25-26 | Q2 FY25-26 | Change % |
|---|---|---|---|
| Total Revenue | 621.30 | 583.30 | 6.51 |
| Expenses | 744.30 | 530.40 | 40.33 |
| Other Income | 74.80 | 133.80 | -44.10 |
| Operating Profit | 345.60 | 579.30 | -40.34 |
| Depreciation | 34.00 | 33.80 | 0.59 |
| Interest | 2.30 | 67.20 | -96.58 |
| Profit Before Tax | -84.50 | 85.70 | -198.60 |
| Tax | -8.10 | 14.80 | -154.73 |
| Net Profit | -76.40 | 70.90 | -207.76 |
| Action | Target Price (₹) | Broker | Date | Reports |
|---|---|---|---|---|
| Data Not Found | ||||
Data not available.
| Company | 1 Day | 1 Week | 1 Month | 3 Months | 6 Month | 1 Year |
|---|---|---|---|---|---|---|
| Data Not Found | ||||||
Biotech firm Biocon on Thursday said it has raised Rs 4,150 crore through a Qualified Institutions Placement (QIP) process. The initiative saw issuance of 1,12,664,585 equity shares of face value Rs 5 each to eligible qualified institutional buyers at the issue price of Rs 368.35 per share, the Bengaluru-based firm said in a regulatory filing. The QIP, which opened on January 12 and closed on January 14, attracted strong investor interest from a broad mix of domestic and international participants, reflecting robust confidence in the company's growth prospects, it added. The proceeds from the QIP will be primarily utilised to meet the cash consideration payable to Mylan Inc. (Viatris) for buying out its shareholding in Biocon Biologics Ltd, including repayment of debt availed in this regard, Biocon said. The company recently announced its board has approved a strategic corporate action to acquire all remaining minority shareholdings, including Viatris' stake, thereby making Biocon
